Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew Lunning

1

Introduction

00:00 • 4min

2

Polaris R-Chips in the Frontline Setting in Large Cell Lymphoma?

04:11 • 2min

3

Dose-Adjusted Epoch R in Hodgkin's Lymphoma?

06:15 • 2min

4

Is RACVBP a Good Trial?

08:29 • 6min

5

Is It a Bridge to an Aloe Transplant?

14:11 • 2min

6

Relapse Rectory Large Olemboma - Is There a Clinical Trial?

15:44 • 2min

7

Zuma 7 Trial

17:42 • 4min

8

Axie Cell High MTV - Is Age a Determinant of CAR T Cell Eligibility?

21:27 • 4min

9

CAR T Cell Transplantation

25:52 • 3min

10

Transplant Equals CAR T Cell Eligibility

28:27 • 4min

11

Axis Cell vs Lysos Cell

32:06 • 3min

12

Is CAR T Cell Therapy Curable of Intent?

34:52 • 2min

13

Is Glofitomab a Matchmaker Drug for Follicular Lymphoma?

36:47 • 3min

14

Mose and Tusumab Monotherapy in DLBCL

40:01 • 2min

15

Relapse Refractory Follicular Lymphoma

42:24 • 5min

16

Indolent Lymphoma - Is Cellular Therapy a Good Thing?

47:50 • 6min

17

Is CRS and ICANN's an Impediment to Oncology?

53:36 • 2min

18

CRS Management and Tosyllizumab

55:18 • 3min

19

Is There a Risk of a Class Not Approved?

57:50 • 2min

20

Mantle Cell Lymphoma

59:24 • 3min

21

Do I Need to Keep the Auto Transplant Right or Is It Worth Keeping the Auto?

01:02:40 • 3min

22

I Think It Will Get Slow if It Gets Approved

01:05:27 • 2min

23

I Think the E-Cog Trial Is Starting to Look a Little Bit Like Ebrutinib and Retuximab in a 65 Year Old Patient Population

01:07:21 • 3min

24

Mantle Cell Lymphoma - Is There a Survival Advantage?

01:10:33 • 2min

25

Transplantation in a Disease With a Tp3 Mutation

01:12:51 • 5min

26

Using Bi Specifics in Mantle Cell Lymphoma

01:17:51 • 5min

27

Antibodies in Refractory Classical Hochskin's Lymphoma

01:23:10 • 3min

28

Car T Cell Therapy in Large B-Cell Lymphoma

01:25:45 • 3min